Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
In 2026, investors eyeing the healthcare sector face a choice between Johnson & Johnson and Eli Lilly. Both companies offer distinct advantages, catering to investors with different risk appetites and growth expectations. Johnson & Johnson, with its diversified portfolio, stands as a stable anchor, while Eli Lilly promises rapid growth through its focus on innovative treatments.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
